RESUMEN
AIM: To evaluate GI safety of celecoxib compared with 2 nonselective (ns) NSAIDs, as a secondary objective of a large trial examining multiorgan safety. METHODS: This randomised, double-blind controlled trial analysed 24 081 patients. Osteoarthritis or rheumatoid arthritis patients, needing ongoing NSAID treatment, were randomised to receive celecoxib 100-200 mg b.d., ibuprofen 600-800 mg t.d.s. or naproxen 375-500 mg b.d. plus esomeprazole, and low-dose aspirin or corticosteroids if already prescribed. Clinically significant GI events (CSGIE-bleeding, obstruction, perforation events from stomach downwards or symptomatic ulcers) and iron deficiency anaemia (IDA) were adjudicated blindly. RESULTS: Mean treatment and follow-up durations were 20.3 and 34.1 months. While on treatment or 30 days after, CSGIE occurred in 0.34%, 0.74% and 0.66% taking celecoxib, ibuprofen and naproxen. Hazard ratios (HR) were 0.43 (95% CI 0.27-0.68, P = 0.0003) celecoxib vs ibuprofen and 0.51 (0.32-0.81, P = 0.004) vs naproxen. There was also less IDA on celecoxib: HR 0.43 (0.27-0.68, P = 0.0003) vs ibuprofen; 0.40 (0.25-0.62, P < 0.0001) vs naproxen. Even taken with low-dose aspirin, fewer CSGIE occurred on celecoxib than ibuprofen (HR 0.52 [0.29-0.94], P = 0.03), and less IDA vs naproxen (0.42 [0.23-0.77, P = 0.005]). Corticosteroid use increased total GI events and CSGIE. H. pylori serological status had no influence. CONCLUSIONS: Arthritis patients taking NSAIDs plus esomeprazole have infrequent clinically significant gastrointestinal events. Co-prescribed with esomeprazole, celecoxib has better overall GI safety than ibuprofen or naproxen at these doses, despite treatment with low-dose aspirin or corticosteroids.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Artritis Reumatoide/tratamiento farmacológico , Celecoxib/administración & dosificación , Enfermedades Gastrointestinales/inducido químicamente , Ibuprofeno/administración & dosificación , Naproxeno/administración & dosificación , Osteoartritis/tratamiento farmacológico , Adulto , Anciano , Antiinflamatorios no Esteroideos/efectos adversos , Antiulcerosos/administración & dosificación , Antiulcerosos/efectos adversos , Artritis Reumatoide/diagnóstico , Artritis Reumatoide/epidemiología , Aspirina/administración & dosificación , Aspirina/efectos adversos , Celecoxib/efectos adversos , Método Doble Ciego , Quimioterapia Combinada , Esomeprazol/administración & dosificación , Esomeprazol/efectos adversos , Femenino , Enfermedades Gastrointestinales/diagnóstico , Enfermedades Gastrointestinales/epidemiología , Humanos , Ibuprofeno/efectos adversos , Masculino , Persona de Mediana Edad , Naproxeno/efectos adversos , Osteoartritis/diagnóstico , Osteoartritis/epidemiología , Resultado del TratamientoRESUMEN
Atherosclerosis is a maladaptive, nonresolving chronic inflammatory disease that occurs at sites of blood flow disturbance. The disease usually remains silent until a breakdown of integrity at the arterial surface triggers the formation of a thrombus. By occluding the lumen, the thrombus or emboli detaching from it elicits ischaemic symptoms that may be life-threatening. Two types of surface damage can cause atherothrombosis: plaque rupture and endothelial erosion. Plaque rupture is thought to be caused by loss of mechanical stability, often due to reduced tensile strength of the collagen cap surrounding the plaque. Therefore, plaques with reduced collagen content are thought to be more vulnerable than those with a thick collagen cap. Endothelial erosion, on the other hand, may occur after injurious insults to the endothelium instigated by metabolic disturbance or immune insults. This review discusses the molecular mechanisms involved in plaque vulnerability and the development of atherothrombosis.
Asunto(s)
Endotelio Vascular , Inflamación/inmunología , Placa Aterosclerótica , Animales , Proteasas de Cisteína/metabolismo , Endotelio Vascular/metabolismo , Endotelio Vascular/patología , Endotelio Vascular/fisiopatología , Humanos , Metaloproteinasas de la Matriz/metabolismo , Placa Aterosclerótica/complicaciones , Placa Aterosclerótica/patología , Placa Aterosclerótica/fisiopatología , Rotura Espontánea/complicaciones , Rotura Espontánea/metabolismo , Rotura Espontánea/fisiopatología , Tromboembolia/etiologíaRESUMEN
BACKGROUND: A growing health problem, venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), requires refined diagnostic and therapeutic approaches. Neutrophils contribute to thrombus initiation and development in experimental DVT. Recent animal studies recognized neutrophil extracellular traps (NETs) as an important scaffold supporting thrombus stability. However, the hypothesis that human venous thrombi involve NETs has not undergone rigorous testing. OBJECTIVE: To explore the cellular composition and the presence of NETs within human venous thrombi at different stages of development. PATIENTS AND METHODS: We examined 16 thrombi obtained from 11 patients during surgery or at autopsy using histomorphological, immunohistochemical and immunofluorescence analyses. RESULTS: We classified thrombus regions as unorganized, organizing and organized according to their morphological characteristics. We then evaluated them, focusing on neutrophil and platelet deposition as well as micro-vascularization of the thrombus body. We observed evidence of NET accumulation, including the presence of citrullinated histone H3 (H3Cit)-positive cells. NETs, defined as extracellular diffuse H3Cit areas associated with myeloperoxidase and DNA, localized predominantly during the phase of organization in human venous thrombi. CONCLUSIONS: NETs are present in organizing thrombi in patients with VTE. They are associated with thrombus maturation in humans. Dissolution of NETs might thus facilitate thrombolysis. This finding provides new insights into the clinical development and pathology of thrombosis and provides new perspectives for therapeutic advances.
Asunto(s)
Trampas Extracelulares , Neutrófilos/patología , Tromboembolia Venosa/patología , Adolescente , Adulto , Anciano , Biomarcadores/análisis , Plaquetas/patología , Citrulina/análisis , ADN/análisis , Progresión de la Enfermedad , Trampas Extracelulares/química , Femenino , Histonas/análisis , Humanos , Inmunohistoquímica , Masculino , Microscopía Fluorescente , Microvasos/patología , Persona de Mediana Edad , Neutrófilos/metabolismo , Peroxidasa/análisis , Tromboembolia Venosa/sangre , Tromboembolia Venosa/metabolismoRESUMEN
Macrophages contribute pivotally to cardiovascular diseases (CVD), notably to atherosclerosis. Imaging of macrophages in vivo could furnish new tools to advance evaluation of disease and therapies. Proteolytic enzymes serve as key effectors of many macrophage contributions to CVD. Therefore, intravital imaging of protease activity could aid evaluation of the progress and outcome of atherosclerosis, aortic aneurysm formation, or rejection of cardiac allografts. Among the large families of proteases, matrix metalloproteinases (MMPs) and cysteinyl cathepsins have garnered the most interest because of their participation in extracellular matrix remodelling. These considerations have spurred the development of dedicated imaging agents for protease activity detection. Activatable fluorescent probes, radiolabelled inhibitors, and nanoparticles are currently under exploration for this purpose. While some agents and technologies may soon see clinical use, others will require further refinement. Imaging of macrophages and protease activity should provide an important adjunct to understanding pathophysiology in vivo, evaluating the effects of interventions, and ultimately aiding clinical care.
Asunto(s)
Enfermedades Cardiovasculares/diagnóstico , Catepsinas/metabolismo , Diagnóstico por Imagen , Macrófagos/metabolismo , Metaloproteinasas de la Matriz/metabolismo , Animales , Enfermedades Cardiovasculares/inmunología , Enfermedades Cardiovasculares/patología , Diagnóstico por Imagen/métodos , Diagnóstico por Imagen/tendencias , Colorantes Fluorescentes , Humanos , Inflamación , Macrófagos/patología , Nanopartículas , Placa Aterosclerótica , Sensibilidad y EspecificidadRESUMEN
Our evolving knowledge of the cellular and molecular mechanisms underlying atherosclerosis has helped uncover the underlying causes behind thrombotic complications of this disease. Most fatal coronary thrombosis result from fibrous cap rupture or superficial erosion. Recent research has established a role for matrix metalloproteinases in the regulation of aspects of plaque structure related to propensity to disrupt and provoke thrombosis. Inflammatory pathways impinge on proteinase activity and aspects of oxidative stress that may favour plaque disruption. Novel molecular imaging strategies may permit visualization of proteinase activity in vivo, providing a new functional window on pathophysiology.
Asunto(s)
Aterosclerosis/patología , Aterosclerosis/fisiopatología , Trombosis Coronaria/fisiopatología , Animales , Apoptosis , Aterosclerosis/complicaciones , Colágeno/metabolismo , Trombosis Coronaria/etiología , Endotelio Vascular/patología , Humanos , Lípidos , Metaloproteinasas de la Matriz/metabolismo , Ratones , Rotura Espontánea/fisiopatologíaRESUMEN
Atherosclerosis depends critically on altered behavior of the intrinsic cells of the artery wall, the endothelial cells and smooth muscle cells, and inflammatory leukocytes that join them in the arterial intima during the atherogenic process. The homeostatic properties of the normal endothelium contribute importantly to maintenance of aspects of arterial health including the appropriate regulation of blood flow, a basal anti-inflammatory state, promotion of fibrinolysis while opposing blood coagulation, and control of the balance of cellular proliferation and death. Alterations in these endothelial homeostatic mechanisms contribute critically to atherogenesis, the progression of this disease, and ist complications. Recent advances have highlighted novel molecular mechanisms that regulate the atheroprotective functions of normal endothelial cells that go awry during atherogenesis. Therapeutic strategies that alter the course of atherosclerosis may act by combating endothelial dysfunction.
Asunto(s)
Aterosclerosis/metabolismo , Endotelio Vascular/metabolismo , Inflamación/metabolismo , Trombosis/metabolismo , Animales , Aspirina/farmacología , Aspirina/uso terapéutico , Aterosclerosis/tratamiento farmacológico , Aterosclerosis/patología , Moléculas de Adhesión Celular/metabolismo , Inhibidores de la Ciclooxigenasa/farmacología , Inhibidores de la Ciclooxigenasa/uso terapéutico , Citocinas/metabolismo , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/patología , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Inflamación/tratamiento farmacológico , Inflamación/patología , Óxido Nítrico/metabolismo , Prostaglandinas I/metabolismo , Trombosis/tratamiento farmacológico , Trombosis/patologíaRESUMEN
The predicted global epidemic of type 2 diabetes highlights the importance of identifying the most effective ways to reduce the risk of long-term diabetic complications. Although hyperglycaemia is undoubtedly a risk factor for microvascular complications, intensive glycaemic management has delivered only modest improvements in macrovascular endpoints thus far. A multidisciplinary approach addressing the components of the dysmetabolic syndrome, including insulin resistance, dyslipidaemia, hypertension, obesity and impaired fibrinolysis, will be required to protect the cardiovascular system more effectively. The potential vascular protective effects of metformin, demonstrated by the UK Prospective Diabetes Study, may complement other strategies within such a framework.
Asunto(s)
Cardiología , Enfermedades Cardiovasculares/prevención & control , Diabetes Mellitus Tipo 2/complicaciones , Hipoglucemiantes/uso terapéutico , Metformina/uso terapéutico , Enfermedades Cardiovasculares/etiología , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Humanos , Hiperglucemia/complicaciones , Hiperglucemia/tratamiento farmacológico , Síndrome Metabólico/tratamiento farmacológicoRESUMEN
During angiogenesis, microvascular endothelial cells (ECs) secrete proteinases that permit penetration of the vascular basement membrane as well as the interstitial extracellular matrix. This study tested the hypothesis that cathepsin S (Cat S) contributes to angiogenesis. Treatment of cultured ECs with inflammatory cytokines or angiogenic factors stimulated the expression of Cat S, whereas inhibition of Cat S activity reduced microtubule formation by impairing cell invasion. ECs from Cat S-deficient mice showed reduced collagenolytic activity and impaired invasion of collagens type I and IV. Cat S-deficient mice displayed defective microvessel development during wound repair. This abnormal angiogenesis occurred despite normal vascular endothelial growth factor and basic fibroblast growth factor levels, implying an essential role for extracellular matrix degradation by Cat S during microvessel formation. These results demonstrate a novel function of endothelium-derived Cat S in angiogenesis.
Asunto(s)
Catepsinas/fisiología , Endotelio Vascular/enzimología , Endotelio Vascular/crecimiento & desarrollo , Animales , Capilares/citología , Catepsinas/genética , Adhesión Celular , Movimiento Celular , Células Cultivadas , Colágeno/metabolismo , Elastina/metabolismo , Endotelio Vascular/citología , Endotelio Vascular/fisiología , Humanos , Ratones , Ratones Noqueados , Cicatrización de HeridasRESUMEN
Today, multiple lines of evidence support the view of atherosclerosis as a chronic inflammatory disease and implicate components of the immune system in atherogenesis. Recent work has documented overexpression of the potent immune mediator CD40 and its counterpart CD40 ligand (CD40L) in experimental and human atherosclerotic lesions. Notably, interruption of CD40/CD40L interactions not only diminished the formation and progression of mouse atheroma, but also fostered changes in lesion biology and structure, which are associated in humans with "plaque stabilization." In accordance with the hypothesis that CD40 signaling promotes plaque instability, in vitro studies demonstrated that ligation of CD40 on atheroma-associated cell types, namely endothelial cells, smooth muscle cells, and macrophages, mediates functions considered crucial to the process of atherogenesis, such as the expression of cytokines, chemokines, growth factors, matrix metalloproteinases, and procoagulants. The combination of the broad gamut of proatherogenic biological responses triggered by ligation of CD40 on endothelial cells, smooth muscle cells, and macrophages in vitro and the results of in vivo studies of interruption of CD40 signaling suggests a central role for this receptor/ligand dyad during atherogenesis, proposing CD40/CD40L interactions as a novel potential therapeutic target for this prevalent human disease.
Asunto(s)
Arteriosclerosis/inmunología , Arteriosclerosis/metabolismo , Antígenos CD40/metabolismo , Transducción de Señal , Animales , Arteriosclerosis/complicaciones , Ligando de CD40/metabolismo , Enfermedad Crónica , Citocinas/metabolismo , Progresión de la Enfermedad , Endotelio Vascular/metabolismo , Humanos , Inflamación/complicaciones , Inflamación/inmunología , Inflamación/metabolismo , Macrófagos/metabolismo , Músculo Liso Vascular/metabolismoRESUMEN
Coronary heart disease (CHD) contributes substantially to illness and death worldwide. Experimental studies demonstrate that infection can stimulate atherogenic processes. This review presents a spectrum of data regarding the link between CHD and infection. In addition, the need for improved diagnostic tools, the significance of multiple pathogens, and potential intervention strategies are discussed.
Asunto(s)
Arteriosclerosis/etiología , Infecciones por Chlamydia/complicaciones , Infecciones por Citomegalovirus/complicaciones , Animales , Arteriosclerosis/microbiología , Arteriosclerosis/virología , Infecciones por Chlamydia/microbiología , Chlamydophila pneumoniae/aislamiento & purificación , Citomegalovirus/aislamiento & purificación , Humanos , Ratones , Ratones Endogámicos C57BL , ConejosRESUMEN
BACKGROUND: The immune-signaling dyad CD40/CD40L promotes atherogenesis, and patients with unstable angina have elevated plasma levels of soluble CD40L (sCD40L) and membrane-bound CD40L. It is unknown, however, whether elevations of circulating sCD40L precede the onset of acute cardiovascular symptoms. METHODS AND RESULTS: In a prospective, nested case-control evaluation of healthy middle-aged women, mean concentrations of sCD40L at baseline were significantly higher among 130 participants who subsequently developed myocardial infarction, stroke, or cardiovascular death (cases), compared with 130 age- and smoking-matched women who remained free of cardiovascular disease (controls) during a 4-year follow-up (2.86 ng/mL for cases versus 2.09 ng/mL for controls; P=0.02). Women with concentrations above the 95th percentile of the control distribution (>3.71 ng/mL) had a significantly increased relative risk (RR) of developing future cardiovascular events (RR, 3.3; 95% CI, 1.2 to 8.6; P=0.01) that remained after adjustment for usual cardiovascular risk factors (multivariate RR, 2.8; 95% CI, 0.9 to 8.0; P=0.05). CONCLUSIONS: High plasma concentrations of sCD40L may be associated with increased vascular risk in apparently healthy women.
Asunto(s)
Ligando de CD40/sangre , Enfermedades Cardiovasculares/sangre , Enfermedades Cardiovasculares/epidemiología , Estudios de Casos y Controles , LDL-Colesterol/sangre , Ensayo de Inmunoadsorción Enzimática , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Oportunidad Relativa , Valor Predictivo de las Pruebas , Estudios Prospectivos , Riesgo , Factores de Riesgo , Fumar/epidemiología , Triglicéridos/sangre , Estados Unidos/epidemiologíaRESUMEN
BACKGROUND: The mechanisms of extracellular matrix changes accompanying myxomatous valvular degeneration are uncertain. METHODS AND RESULTS: To test the hypothesis that valvular interstitial cells mediate extracellular matrix degradation in myxomatous degeneration by excessive secretion of catabolic enzymes, we examined the functional characteristics of valvular interstitial cells in 14 mitral valves removed for myxomatous degeneration from patients with mitral regurgitation and in 11 normal mitral valves obtained at autopsy. Immunohistochemical staining assessed (1) cell phenotype using antibodies to alpha-actin (microfilaments), vimentin and desmin (intermediate filaments), smooth muscle myosin (SM1), and SMemb (a nonmuscle myosin produced by activated mesenchymal cells) and (2) the expression of proteolytic activity using antibodies to collagenases (matrix metalloproteinase [MMP]-1, MMP-13), gelatinases (MMP-2, MMP-9), cysteine endoproteases (cathepsin S and K), and interleukin-1beta, a cytokine that can induce secretion of proteolytic enzymes. Although interstitial cells in normal valves stained positively for vimentin, but not alpha-actin or desmin, cells in myxomatous valves contained both vimentin and alpha-actin or desmin (characteristics of myofibroblasts). Moreover, cells in myxomatous valves strongly expressed SMemb, MMPs, cathepsins, and interleukin-1beta, which were weakly stained in controls. Nevertheless, interstitial cells in both groups strongly expressed procollagen-I mRNA (in situ hybridization), suggesting preserved ability to synthesize collagen in myxomatous valves. CONCLUSIONS: Interstitial cells in myxomatous valves have features of activated myofibroblasts and express excessive levels of catabolic enzymes, without altered levels of interstitial collagen mRNA. We conclude that valvular interstitial cells regulate matrix degradation and remodeling in myxomatous mitral valve degeneration.
Asunto(s)
Matriz Extracelular/metabolismo , Fibroblastos/fisiología , Neoplasias Cardíacas/metabolismo , Insuficiencia de la Válvula Mitral/etiología , Válvula Mitral/citología , Mixoma/metabolismo , Adulto , Anciano , Catepsinas/metabolismo , Colágeno Tipo I/biosíntesis , Colágeno Tipo I/genética , Femenino , Fibroblastos/enzimología , Neoplasias Cardíacas/complicaciones , Neoplasias Cardíacas/enzimología , Neoplasias Cardíacas/patología , Humanos , Masculino , Metaloproteinasas de la Matriz/metabolismo , Persona de Mediana Edad , Válvula Mitral/metabolismo , Válvula Mitral/patología , Modelos Cardiovasculares , Mixoma/complicaciones , Mixoma/enzimología , Mixoma/patología , ARN Mensajero/biosíntesisRESUMEN
Several lines of clinical evidence show that AMI frequently occurs at sites with mild to moderate degree of coronary stenosis. The degree of luminal stenosis depends on plaque deposition and degree of vessel remodeling, features poorly assessed by coronary angiography. This postmortem study tested the hypothesis that the size of coronary atheroma and the type of remodeling distinguish culprit lesion responsible for fatal AMI from equi-stenotic nonculprit lesion in the same coronary tree. The main coronary branches from 36 consecutive patients with fatal AMI were studied. The culprit lesion (Group 1) and an equi-stenotic nonculprit segment (Group 2) obtained in measurements of another coronary branch from the same patient were compared. Morphometry and plaque composition was assessed in both groups. Compared to Group 2, Group 1 had larger areas of: plaque 9.6 vs. 4.7 mm(2), vessel 12.7 vs. 7.4 mm(2) and lumen 1.7 vs. 1.2 mm(2); (P< .01). Positive remodeling was more frequent in Group 1 than Group 2: 21/30 (70%) vs. 8/26 (31%). Plaque area correlated positively with lipid core and macrophages and negatively with fibrosis and smooth muscle cells. Atherosclerotic plaques that cause fatal thrombosis are more frequently positively remodeled and tend to be larger than nonculprit plaques with the same degree of cross-sectional stenosis. We tested whether arterial remodeling and plaque size vary between segments containing a fatal thrombosed plaque versus an equi-stenotic nonculprit plaque. Culprit vessel segments had higher cross-sectional areas of intimal plaque and of vessel wall than equi-stenotic nonculprit plaques. The cross-sectional area of the vessel correlated positively with both the lipid core area and CD68(+) macrophage content, and negatively with fibrosis area and smooth muscle cell content. These results add elements explaining limitations of angiography in identifying plaques and provide new insights into the role of remodeling in plaque instability.
Asunto(s)
Enfermedad de la Arteria Coronaria/patología , Trombosis Coronaria/etiología , Vasos Coronarios/patología , Antígenos CD/inmunología , Antígenos de Diferenciación Mielomonocítica/inmunología , Constricción Patológica , Enfermedad de la Arteria Coronaria/complicaciones , Trombosis Coronaria/patología , Femenino , Fibrosis , Humanos , Inmunohistoquímica , Lípidos/sangre , Macrófagos/inmunología , Masculino , Persona de Mediana Edad , Infarto del Miocardio/patología , Estudios RetrospectivosRESUMEN
BACKGROUND: Loss of interstitial collagen, particularly type I collagen, the major load-bearing molecule of atherosclerotic plaques, renders atheroma prone to rupture. Initiation of collagen breakdown requires interstitial collagenases, a matrix metalloproteinase (MMP) subfamily consisting of MMP-1, MMP-8, and MMP-13. Previous work demonstrated the overexpression of MMP-1 and MMP-13 in human atheroma. However, no study has yet evaluated the expression of MMP-8, known as "neutrophil collagenase," the enzyme that preferentially degrades type I collagen, because granulocytes do not localize in plaques. METHODS AND RESULTS: Transcriptional profiling and reverse transcription-polymerase chain reaction analysis revealed inducible expression of MMP-8 transcripts in CD40 ligand-stimulated mononuclear phagocytes. Western blot analysis demonstrated that 3 atheroma-associated cell types, namely, endothelial cells, smooth muscle cells, and mononuclear phagocytes, expressed MMP-8 in vitro upon stimulation with proinflammatory cytokines such as interleukin-1beta, tumor necrosis factor-alpha, or CD40 ligand. MMP-8 protein elaborated from these atheroma-associated cell types migrated as 2 immunoreactive bands, corresponding to the molecular weights of the zymogen and the active molecule. Extracts from atherosclerotic, but not nondiseased arterial tissue, contained similar immunoreactive bands. Moreover, all 3 cell types expressed MMP-8 mRNA and protein in human atheroma in situ. Notably, MMP-8 colocalized with cleaved but not intact type I collagen within the shoulder region of the plaque, a frequent site of rupture. CONCLUSIONS: These data point to MMP-8 as a previously unsuspected participant in collagen breakdown, an important determinant of the vulnerability of human atheroma.
Asunto(s)
Arteriosclerosis/enzimología , Colágeno/metabolismo , Perfilación de la Expresión Génica , Metaloproteinasa 8 de la Matriz/biosíntesis , Metaloproteinasa 8 de la Matriz/genética , Aorta/enzimología , Aorta/patología , Arteriosclerosis/patología , Ligando de CD40 , Arterias Carótidas/enzimología , Arterias Carótidas/patología , Células Cultivadas , Citocinas/farmacología , Endotelio Vascular/enzimología , Endotelio Vascular/patología , Humanos , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/enzimología , Músculo Liso Vascular/enzimología , Músculo Liso Vascular/patología , Fagocitos/enzimología , Fagocitos/patología , ARN Mensajero/biosíntesis , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
In the past, we believed that atherosclerosis gradually and progressively led to the complete occlusion of an artery, thereby causing acute coronary events. However, we now understand that rupture of a nonstenotic, yet vulnerable atherosclerotic plaque frequently leads to an acute coronary syndrome. Rupture-prone plaques typically have a thin fibrous cap, numerous inflammatory cells, a substantial lipid core, and surprisingly few smooth muscle cells. Physical disruption of such a plaque allows circulating blood coagulation factors to meet with the highly thrombogenic material in the plaque's lipid core, thereby instigating the formation of a potentially occluding and fatal thrombus. Much evidence implicates inflammation in the thinning of the fibrous cap and the disruption of the vulnerable atherosclerotic plaque. Lipid lowering undisputedly reduces the incidence of acute coronary events. However, the hypothesis that the mechanism of event reduction involves regression of fixed stenoses has proved untenable. In 14 angiographic studies, treatment of abnormal lipid levels increased luminal diameter only modestly, in stark contrast to the resounding and consistent decrease in acute coronary events produced by lipid lowering. Therefore, we now believe that lipid-lowering treatments, such as statins, modify plaques qualitatively as much as quantitatively, reducing inflammation and stabilizing noncritically stenotic, yet vulnerable plaques. Studies in rabbits with diet-induced atherosclerosis have shown that reducing cholesterol consumption indeed decreases inflammation in atheroma and improves those features of plaques associated with stability.
Asunto(s)
Arteriosclerosis/inmunología , Enfermedad de la Arteria Coronaria/inmunología , Estenosis Coronaria/inmunología , Mediadores de Inflamación/fisiología , Animales , Anticolesterolemiantes/uso terapéutico , Arteriosclerosis/tratamiento farmacológico , Atorvastatina , Colesterol en la Dieta/administración & dosificación , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Estenosis Coronaria/tratamiento farmacológico , Ácidos Heptanoicos/uso terapéutico , Humanos , Pirroles/uso terapéutico , ConejosRESUMEN
Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors that regulate gene expression in response to activation by specific ligands including insulin sensitizing thiazolidinedione and lipid-lowering fibrates. Recent work has identified PPARalpha and PPARgamma expression in vascular cells and established a role for these receptors in the regulation of genes relevant to atherogenesis. The following review will focus on the role of PPAR activation in the vasculature and discuss the potential clinical implications of these findings.
Asunto(s)
Arteriosclerosis/fisiopatología , Músculo Liso Vascular/fisiopatología , Receptores Citoplasmáticos y Nucleares/metabolismo , Factores de Transcripción/metabolismo , Arteriosclerosis/inmunología , Humanos , Metabolismo de los Lípidos , Músculo Liso Vascular/metabolismo , Molécula 1 de Adhesión Celular Vascular/metabolismoAsunto(s)
Matriz Extracelular/metabolismo , Metaloproteinasas de la Matriz/metabolismo , Neovascularización Fisiológica/fisiología , Oxígeno/metabolismo , Animales , Membrana Basal/metabolismo , Factores de Crecimiento Endotelial/metabolismo , Endotelio Vascular/citología , Endotelio Vascular/metabolismo , Inflamación/metabolismo , Interleucina-10/farmacología , Isquemia/metabolismo , Linfocinas/metabolismo , Ratones , Neovascularización Fisiológica/efectos de los fármacos , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
The endothelium produces a number of vasodilator and vasoconstrictor substances that not only regulate vasomotor tone, but also the recruitment and activity of inflammatory cells and the propensity towards thrombosis. Endothelial vasomotor function is a convenient way to assess these other functions, and is related to the long-term risk of cardiovascular disease. Lipids (particularly low density lipoprotein cholesterol) and oxidant stress play a major role in impairing these functions, by reducing the bioavailability of nitric oxide and activating pro-inflammatory signalling pathways such as nuclear factor kappa B. Biomechanical forces on the endothelium, including low shear stress from disturbed blood flow, also activate the endothelium increasing vasomotor dysfunction and promoting inflammation by upregulating pro-atherogenic genes. In contrast, normal laminar shear stress promotes the expression of genes that may protect against atherosclerosis. The sub-cellular structure of endothelial cells includes caveolae that play an integral part in regulating the activity of endothelial nitric oxide synthase. Low density lipoprotein cholesterol and oxidant stress impair caveolae structure and function and adversely affect endothelial function. Lipid-independent pathways of endothelial cell activation are increasingly recognized, and may provide new therapeutic targets. Endothelial vasoconstrictors, such as endothelin, antagonize endothelium-derived vasodilators and contribute to endothelial dysfunction. Some but not all studies have linked certain genetic polymorphisms of the nitric oxide synthase enzyme to vascular disease and impaired endothelial function. Such genetic heterogeneity may nonetheless offer new insights into the variability of endothelial function.
Asunto(s)
Enfermedad Coronaria/fisiopatología , Endotelio Vascular/fisiopatología , Animales , Fenómenos Biomecánicos , Endotelio Vascular/ultraestructura , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Óxido Nítrico/fisiología , Óxido Nítrico Sintasa/genética , Estrés Oxidativo , Polimorfismo Genético , VasoconstrictoresRESUMEN
BACKGROUND: Although hypertension is an important risk factor for the development of atherosclerosis, the mechanisms for this interaction are incompletely described. Previous studies have suggested that biomechanical strain regulates macrophage phenotype. We tested the hypothesis that biomechanical strain can induce expression of the class A scavenger receptor (SRA), an important lipoprotein receptor in atherogenesis. METHODS AND RESULTS: Human monocyte/macrophages or THP-1 cells were cultured in a device that imposes uniform biaxial cyclic 1-Hz strains of 0%, 1%, 2%, or 3%, and SRA expression was analyzed. Mechanical strains induced SRA mRNA (3.5+/-0.6-fold at 3% strain for 48 hours, P<0.01) and SRA protein in THP-1 cells in an amplitude-dependent manner. This induction was accompanied by augmented expression of the class B scavenger receptor CD36 (2.8+/-0.3-fold, P<0.001) but not by increased peroxisome proliferator-activated receptor-gamma expression. To evaluate this effect in vivo, apolipoprotein E(-/-) mice were randomly assigned to receive standard chow, a high-cholesterol diet, or a high-cholesterol diet with hypertension induced by angiotensin II infusion for 8 weeks. Immunohistochemistry revealed that among macrophages in atherosclerotic lesions of the aorta, the proportion of macrophages with SRA expression was highest in hypertensive animals on a high-cholesterol diet (43.9+/-0.7%, versus 12.0+/-2.0% for normotensive animals on a high-cholesterol diet and 4.7+/-4.7% for animals on standard chow; P<0.001). CONCLUSIONS: Biomechanical strain induces SRA expression by monocyte/macrophages, suggesting a novel mechanism for promotion of atherosclerosis in hypertensive patients.